Chloramphenicol Inj Rx
Generic Name and Formulations:
Chloramphenicol sodium succinate 100mg/mL; pwd for IV inj after reconstitution; sodium content 2.25 mEq/g chloramphenicol; preservative-free.
Various generic manufacturers
Indications for Chloramphenicol Inj:
Serious susceptible infections resistant to other antibiotics. Typhoid fever. Cystic fibrosis regimens.
Give by IV inj over ≥1-minute interval. 50mg/kg per day in 4 divided doses every 6 hours. Moderately resistant infections: may increase up to 100mg/kg per day, reduce dose as soon as possible. Typhoid fever: give for 8–10 days after patient has become afebrile. Renal or hepatic impairment: adjust or reduce dose. Switch to oral form as soon as possible.
Give by IV inj over ≥1-minute interval. Premature, full-term infants <2 weeks old, or children with immature metabolic processes: 25mg/kg per day in 4 divided doses every 6 hours. Children >2 weeks old: up to 50mg/kg per day in 4 divided doses every 6 hours. Severe infections (eg, bacteremia, meningitis): up to 100mg/kg per day, reduce to 50mg/kg per day as soon as possible. Typhoid fever: give for 8–10 days after patient has become afebrile. Switch to oral form as soon as possible.
Not for trivial infections or prophylaxis. Previous toxic reactions to chloramphenicol.
Renal or hepatic impairment. Obtain baseline CBCs then every 2 days during therapy; discontinue if blood dyscrasias, optic neuritis or peripheral neuritis develops. Avoid repeat therapy. Monitor serum levels. Premature and newborn infants. Labor & delivery. Pregnancy. Nursing mothers.
Avoid other bone marrow suppressants.
Serious/fatal blood dyscrasias, paroxysmal nocturnal hemoglobinemia, GI upset, headache, confusion, delirium, optic and peripheral neuritis, gray baby syndrome, rashes, anaphylaxis, Herxheimer reactions (w. typhoid fever).
Formerly known under the brand names Chlormycetin, Mychel S.
Endocrinology Advisor Articles
- Effect of HbA1c and Perioperative Glucose on Postoperative Mortality
- GLP-1 Agonists Superior to DPP-4 Inhibitors for Reducing HbA1c, Weight in T2D
- Semaglutide May Be Useful for Treating Obesity in People Without Diabetes
- Effect of Growth Hormone Treatment on BMD in Adults With Prader-Willi Syndrome
- Once-Daily Oral Contraceptive for Men Shows Promise
- American College of Physicians Releases 4 Guidelines for HbA1c Targets in T2D
- Dyslipidemia Drug Indications
- No Difference in Weight Loss Outcomes With Low-Fat vs Low-Carbohydrate Diet
- Damaging Effects of Gastric Bypass Surgery on Bone Mass and Microarchitecture
- Gastric Bypass Surgery Linked to Increased Risk for Nonvertebral Fractures
- Metformin May Improve Pregnancy Outcomes in Polycystic Ovary Syndrome
- HbA1c Levels Affect Serum Phospholipids, Inflammation inT2D, CVD
- No Cardiovascular Benefit With Fenofibrate in T2D and Hypertriglyceridemia
- Cardiovascular Function May Improve After Cure of Cushing Syndrome
- Primary Prevention Outcomes With Aspirin in T2D and Heart Failure